Christine Cvijic
Finanzdirektor/CFO bei Neurogene, Inc.
Vermögen: 2 Mio $ am 31.05.2024
Aktive Positionen von Christine Cvijic
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Neurogene, Inc.
Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | Finanzdirektor/CFO | 24.09.2019 | - |
Präsident | 24.09.2019 | - |
Karriereverlauf von Christine Cvijic
Ehemalige bekannte Positionen von Christine Cvijic
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ADVANCED ACCELERATOR APPLICATION SA(ADR) | Direktor/Vorstandsmitglied | 25.05.2017 | 01.03.2018 |
Independent Dir/Board Member | 25.05.2017 | 01.03.2018 | |
SIO GENE THERAPIES INC. | Verwaltungsdirektor | 01.03.2015 | 01.03.2017 |
General Counsel | 01.03.2015 | 01.03.2017 | |
NPS PHARMACEUTICALS, INC. | General Counsel | 01.02.2014 | 01.02.2015 |
Unternehmenssekretär | 01.02.2014 | 01.02.2015 | |
SAVIENT PHARMACEUTICALS INC | Corporate Officer/Principal | 17.02.2011 | 02.02.2012 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | General Counsel | 01.02.2011 | 01.02.2011 |
Unternehmenssekretär | 01.02.2011 | 01.02.2011 | |
Neumentum, Inc.
Neumentum, Inc. Pharmaceuticals: MajorHealth Technology Neumentum, Inc. engages in the provision of pharmaceutical services. It specializes in non-opioid analgesic and neurology specialty where patient with acute and chronic pain. The company was founded by R. Scott Shively and Joseph V. Pergolizzi, Jr. on April 6, 2017 and is headquartered in Palo Alto, CA. | Direktor/Vorstandsmitglied | 01.03.2017 | - |
Gründer | 01.03.2017 | - | |
DENDREON CORPORATION | General Counsel | 28.02.2012 | - |
Unternehmenssekretär | 28.02.2012 | - |
Ausbildung von Christine Cvijic
Fordham University | Graduate Degree |
Rutgers State University of New Jersey | Undergraduate Degree |
Fordham University School of Law | Graduate Degree |
Statistik
International
Vereinigte Staaten | 10 |
Frankreich | 3 |
Operativ
General Counsel | 4 |
Corporate Secretary | 3 |
Graduate Degree | 2 |
Sektoral
Health Technology | 9 |
Consumer Services | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 8 |
---|---|
Savient Pharmaceuticals, Inc.
Savient Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company, which develops, manufactures and markets pharmaceutical products. The company focuses on developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients who do not respond to conventional therapy. It also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The company was founded in 1980 is headquartered in East Brunswick, NJ. | Health Technology |
Dendreon Corp.
Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Health Technology |
Sio Gene Therapies, Inc.
Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company was founded on October 31, 2014 and is headquartered in New York, NY. | Health Technology |
NPS Pharmaceuticals, Inc.
NPS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NPS Pharmaceuticals, Inc. developed drugs for bone and mineral disorders. It also developed Natpara for the treatment of adult hypoparathyroidism. The company was founded by Hunter Jackson and Thomas N. Parks on October 22, 1986 and is headquartered in Bedminster, NJ. | Health Technology |
Advanced Accelerator Applications SA
Advanced Accelerator Applications SA Medical SpecialtiesHealth Technology Advanced Accelerator Applications SA is a radiopharmaceutical company, which develops, produces and commercializes molecular nuclear medicine products. The firm offers research and development in medicinal and pharmaceutical therapeutic products mainly focusing in cardiology and neurology. It manufactures both diagnostic and therapeutic MNM products for commercialization. The company was founded by Stefano Buono in 2002 and is headquartered in Rueil-Malmaison Cedex, France. | Health Technology |
Neumentum, Inc.
Neumentum, Inc. Pharmaceuticals: MajorHealth Technology Neumentum, Inc. engages in the provision of pharmaceutical services. It specializes in non-opioid analgesic and neurology specialty where patient with acute and chronic pain. The company was founded by R. Scott Shively and Joseph V. Pergolizzi, Jr. on April 6, 2017 and is headquartered in Palo Alto, CA. | Health Technology |
Neurogene, Inc.
Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | Health Technology |
- Börse
- Insiders
- Christine Cvijic
- Erfahrung